Ceribell CBLL 深 沪
等待开盘 08-14 09:30:00 美东时间
23.25
+0.340
+1.48%
华盛通- 最 高23.50
- 今 开23.00
- 成交量 51.04万股
- 最 低 22.685
- 昨 收 22.91
- 总市值 88.22万
- 52周最高 24.33
- 市盈率 静 --
- 换手率 1345.30%
- 52周最低 10.85
- 委 比 -92.71%
- 总股本 3.79万
- 历史最高 32.7489
- 量 比 0.78
- 振 幅 3.56%
- 历史最低 10.01
- 每 手 1
- 风险率 3.61%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅207.38%！Truist Securities上调AbCellera Biologics目标价至30美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持AbCellera Biologics"买入"评级，目标价从12美元升至30美元；Stifel：维持Proficient Auto Logistics"买入"评级，目标价从9美元升至12美元
08-12 08:45
BTIG Reiterates Buy on CeriBell, Maintains $28 Price Target
BTIG analyst Marie Thibault reiterates CeriBell (NASDAQ:CBLL) with a Buy and maintains $28 price target.
08-11 18:33
CeriBell Raises FY2026 Sales Guidance from $112.000M-$116.000M to $114.000M-$117.000M vs $113.979M Est
CeriBell (NASDAQ:CBLL) raises FY2026 sales outlook from $112.000 million-$116.000 million to $114.000 million-$117.000 million vs $113.979 million estimate.
08-11 04:09
CeriBell Announces FDA 510(k) Clearance For Two New AI Algorithm Enhancements Integrated Directly Into Existing Cloud-Based Neurology Portal: Epileptiform Abnormality Detection And Artifact Reduction
CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell" or the "Company"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for two new AI algorithm enhancemen...
08-10 19:09
Ceribell Secures CMS New Technology Add-On Payment (NTAP) for Breakthrough Point-of-Care Delirium Monitor System
Ceribell, Inc. announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted a New Technology Add-on Payment (NTAP) of up to $2,171 per eligible Medicare patient case for its Delirium Monitor System. This follows the FDA clearance of the system in December 2025, making it the first FDA-cleared device for delirium screening and monitoring. The system continuously analyzes EEG segments to detect delirium patterns, supporting ra...
08-03 11:00
Ceribell Expands Board of Directors with Appointments of Thomas West and Sharon O’Keefe
Ceribell, a medical technology company, announced the appointments of Thomas West and Sharon O’Keefe to its Board of Directors. West, with extensive experience scaling medical technologies, previously led Nalu Medical and Intersect ENT, both acquired by large companies. O’Keefe, a seasoned health system leader, managed over $2 billion in revenue at the University of Chicago Medical Center. Their expertise will support Ceribell’s expansion of its ...
07-29 11:00
Ceribell to Report Second Quarter 2026 Financial Results on August 10, 2026
Ceribell, Inc. will release its second-quarter 2026 financial results on August 10, 2026, followed by a conference call at 1:30 p.m. PT / 4:30 p.m. ET. Investors can join via phone using the provided numbers and access code or through a live webcast on the company's website. Ceribell, based in Sunnyvale, California, specializes in neurological patient care with its FDA-cleared Ceribell System, an EEG platform for rapid diagnosis and monitoring. F...
07-20 20:05
CeriBell Highlights Publication Of New Research Paper, 'Point-Of-Care EEG Artificial Intelligence Measure Of Seizure Burden Associates With Clinical Outcome At Discharge'
CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that a new research paper
06-08 19:09
美股大行评级 | 富国银行上调英伟达目标价从265美元升至315美元；Alamar、AEVEX获多家大行首予“买入”评级
今日重点评级关注：Needham：维持Artiva Biotherapeutics"买入"评级，目标价从18美元升至41美元；HC Wainwright & Co.：维持SAB Biotherapeutics"买入"评级，目标价从7美元升至10美元
05-13 11:46
Canaccord Genuity Maintains Buy on CeriBell, Lowers Price Target to $25
Canaccord Genuity analyst William Plovanic maintains CeriBell (NASDAQ:CBLL) with a Buy and lowers the price target from $28 to $25.
05-13 03:22
